Helix BioPharma (TSE:HBP) Hits New 1-Year Low – Time to Sell?

Shares of Helix BioPharma Corp. (TSE:HBP – Get Free Report) reached a new 52-week low during trading on Friday. The stock traded as low as C$0.85 and last traded at C$0.85, with a volume of 3,634 shares changing hands. The stock had previously closed at C$0.98.

Helix BioPharma Stock Performance

The stock has a market cap of C$62.63 million, a price-to-earnings ratio of -20.50 and a beta of 1.15. The stock’s 50 day moving average is C$1.39 and its two-hundred day moving average is C$1.53. The company has a current ratio of 0.45, a quick ratio of 1.03 and a debt-to-equity ratio of 2.44.

About Helix BioPharma

(Get Free Report)

Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery.

See Also

• Five stocks we like better than Helix BioPharma
• Bloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline
• Why Western Digital’s AI Storage Boom Defies the Chip Sell-Off
• Grand Canyon Education Strengthens Its Outlook, But Wall Street Remains Divided
• Amex Stock Slides on Job Cuts, But the Real Story Is Macro